Skip to main content
SpringerLink
Log in

Calcium Channel Antagonist Controversy: Symposium at the Congress of the International Society of Cardiovascular Pharmacotherapy on March 30, 1999, in Amsterdam

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sackett DL, Vennberg JE. Choosing the best research design for each question (editorial). Br Med J 1997;315:1636.

    Google Scholar 

  2. Venning GR. Identification of adverse reactions to new drugs II: How were 18 important adverse reactions discovered and with what delays? Br Med J 1983;286:289-292.

    Google Scholar 

  3. Furberg CD, Psaty BM. Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con side. Arch Intern Med 1995;155:2157-2161.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. La Fondation Suisse de Cardiologic, 98 Plateau de Fronterex, CH = 1208, Geneva, Switzerland

    Wilhelm Rutishauser

Authors
  1. Wilhelm Rutishauser
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rutishauser, W. Calcium Channel Antagonist Controversy: Symposium at the Congress of the International Society of Cardiovascular Pharmacotherapy on March 30, 1999, in Amsterdam. Cardiovasc Drugs Ther 14, 91–92 (2000). https://doi.org/10.1023/A:1007855508036

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007855508036

Keywords

Search

Navigation